C646 modulates inflammatory response and antibacterial activity of macrophage

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• C646 is a novel competitive inhibitor targeting p300/CREB-binding protein.
• Previous research indicated C646's potential antitumor effects.
• The immunomodulatory functions of C646 were largely unexplored.

Purpose of the Study:

• To investigate the effects of C646 on cytokine expression in mouse macrophages.
• To determine C646's impact on the antibacterial activity of macrophages.
• To elucidate the mechanisms underlying C646's immunomodulatory actions.

Main Methods:

• Treatment of mouse macrophages with C646.
• Analysis of pro-inflammatory cytokine levels (e.g., TNF-α, IL-6).
• Assessment of signaling pathways including JNK, ERK1/2, and NF-κB.
• Evaluation of macrophage phagocytic and bactericidal activities against E. coli.
• Measurement of cell surface receptor expression (CD14, TLR4, MD2, FcγR, CR3).

Main Results:

• C646 significantly reduced lipopolysaccharide (LPS)-induced pro-inflammatory cytokines.
• These reductions were linked to the suppression of JNK, ERK1/2, and NF-κB p65 signaling.
• C646 did not affect CD14/TLR4/MD2 complex expression or LPS binding.
• C646 down-regulated FcγR III/II and CR3 expression on macrophages.
• Macrophage phagocytosis of E. coli, phagosome-lysosome fusion, and bactericidal ability were impaired by C646.

Conclusions:

• C646 exhibits significant immunomodulatory effects on macrophages.
• It suppresses pro-inflammatory cytokine production through specific signaling pathways.
• C646 inhibits macrophage antibacterial functions, including phagocytosis and bacterial killing.